TY - JOUR
T1 - Phase i clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
AU - Tsimberidou, Apostolia M.
AU - Moulder, Stacy
AU - Fu, Siqing
AU - Wen, Sijin
AU - Naing, Aung
AU - Bedikian, Agop Y.
AU - Daring, Shawn
AU - Uehara, Cynthia
AU - Ng, Chaan
AU - Wallace, Michael
AU - Camacho, Luis
AU - Kurzrock, Razelle
N1 - Funding Information:
Acknowledgments Supported in part by Grant Number RR024148 from the National Center for Research Resources, a component of the NIH Roadmap for Medical Research (http://nihroadmap.nih.gov/clini-calresearch/overview).
PY - 2010/11
Y1 - 2010/11
N2 - Purpose: We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement. Methods: Patients were treated with HAI cisplatin 100-125 mg/m2 (and 3,000 IU heparin) intraarterially and liposomal doxorubicin (doxil) 20-35 mg/m2 IV (day 1) every 28 days. A "3 + 3" study design was used. Results: Thirty patients were treated (median age, 56 years). Diagnoses were breast cancer (n = 11), colorectal cancer (n = 8), ocular melanoma (n = 4), and other (n = 7). The median number of prior therapies was 5. The maximum tolerated dose (MTD) was at the 100/35 mg/m 2 level. Dose-limiting toxicities were Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (n = 1) at the cisplatin 125 mg/m 2 and systemic doxil 35 mg/m2 dose level. The most common toxicities were nausea/vomiting and fatigue. Of 24 patients evaluable for response, 4 (17%) had a partial response (PR) and 7 (29%) had stable disease (SD) for ≥4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD for ≥4 months. Of 4 patients with ocular melanoma, 1 had a PR and 1 SD for 4 months. One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. Conclusion: The MTD was HAI cisplatin 100 mg/m2 and systemic doxil 35 mg/m2. This regimen demonstrated antitumor activity, especially in breast cancer.
AB - Purpose: We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement. Methods: Patients were treated with HAI cisplatin 100-125 mg/m2 (and 3,000 IU heparin) intraarterially and liposomal doxorubicin (doxil) 20-35 mg/m2 IV (day 1) every 28 days. A "3 + 3" study design was used. Results: Thirty patients were treated (median age, 56 years). Diagnoses were breast cancer (n = 11), colorectal cancer (n = 8), ocular melanoma (n = 4), and other (n = 7). The median number of prior therapies was 5. The maximum tolerated dose (MTD) was at the 100/35 mg/m 2 level. Dose-limiting toxicities were Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (n = 1) at the cisplatin 125 mg/m 2 and systemic doxil 35 mg/m2 dose level. The most common toxicities were nausea/vomiting and fatigue. Of 24 patients evaluable for response, 4 (17%) had a partial response (PR) and 7 (29%) had stable disease (SD) for ≥4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD for ≥4 months. Of 4 patients with ocular melanoma, 1 had a PR and 1 SD for 4 months. One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. Conclusion: The MTD was HAI cisplatin 100 mg/m2 and systemic doxil 35 mg/m2. This regimen demonstrated antitumor activity, especially in breast cancer.
KW - Cisplatin
KW - Doxil
KW - Hepatic arterial infusion
KW - Phase I trial
UR - http://www.scopus.com/inward/record.url?scp=78149415403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78149415403&partnerID=8YFLogxK
U2 - 10.1007/s00280-010-1266-4
DO - 10.1007/s00280-010-1266-4
M3 - Article
C2 - 20204368
AN - SCOPUS:78149415403
SN - 0344-5704
VL - 66
SP - 1087
EP - 1093
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 6
ER -